For additional information regarding any of these oncology studies, please contact Dr. Kara Magee or members of the Oncology Service at (608) 263-7600.
1) STUDIES FOR SPECIFIC CANCER TYPES
Dogs with Lung Masses
Dogs with a lung mass from cancer or fungal infection may qualify for this study. The study. Breathing creates distortion in a traditional CT scan thus making it more difficult to identify lung tumors. This study compares a traditional diagnostic CT scan to slow CT scan and fluoroscopy to determine the best planning method for radiation therapy. Owners of dogs entered into this study will receive a $150 credit to cover additional anesthesia costs. Please contact the UW Veterinary Care Radiation Oncology Service for more information: firstname.lastname@example.org or 608-263-7600.
B-Cell Lymphoma in Dogs: Evaluating the effect of regulatory T cell and killer T cell numbers in blood and tumor tissues of dogs with B cell lymphoma on progression-free survival
Lymphoma accounts for nearly 25% of all canine neoplasms, and 60-80% of these are of B-cell origin. With standard chemotherapy, median survival times for canine B-cell lymphoma (BCL) range from 12 to 18 months. However, critical decisions about patient care currently rely on prognostic indicators that are often unreliable or poorly predict the biological behavior of BCL. Significant improvements in patient care will require identification of new biomarkers that are predictive of clinical behavior. Recent studies in dogs and humans demonstrate a link between anti-tumor immune responses and the biological behavior of tumor.
Regulatory T lymphocytes (Tregs) are immune cells normally tasked with preventing harmful autoimmune responses. However, in some tumors increased frequency of Tregs can impair protective anti-tumor immune responses. The relationship between Treg infiltration and progression-free survival is not clearly defined in dogs with BCL. We hypothesize that Treg frequency and ratio to CD8+ T cells in BCL will be correlated with clinical behavior. We also postulate that Treg frequency and Treg:CD8+ ratios will act as prognostic indicators of survival and may help identify novel targets for anti-cancer therapy.
Eligibility: Criteria for inclusion in this study include newly diagnosed multicentric BCL (World Health Organization [WHO] stage I-IV) and willingness to start standard-of-care CHOP chemotherapy. Owners must be willing to return to UW Veterinary Care one week after initiation of chemotherapy, as well as at the time of relapse. Patients with WHO stage V BCL (leukemic patients), or evidence of concurrent disease other than BCL or who have undergone previous chemotherapy or steroid treatment will not be eligible. Dogs enrolled in the study will undergo a blood draw and lymph node aspiration at enrollment, following 1 week of chemotherapy, and at the time of clinical relapse. Once a dog is accepted as eligible, the study will pay for immunocytochemical analysis of lymph node aspirates to confirm the tumor’s immunophenotype.
Lymphoma: Evaluation of Adding Tanovea to Standard of Care Chemotherapy in Dogs with Newly Diagnosed Lymphoma
Lymphoma is one of the most common cancers in dogs. Current treatment options include various types of chemotherapy including Tanovea-CA1 (rabacfosadine for injection), the first FDA conditionally approved drug to treat canine lymphoma. It is an intravenous chemotherapy agent that has been used in more than 600 dogs with cancer. The goal of this study is to evaluate the effectiveness and safety of the addition of Tanovea to a chemotherapy protocol containing prednisone, vincristine, cyclophosphamide, and doxorubicin in dogs with previously untreated multicentric lymphoma.
Dogs with newly diagnosed lymphoma may be eligible for this study. The study provides Tanovea at no cost. Owners are responsible for all other costs including the intravenous administration of Tanovea.
Melanoma: Evaluation of a Targeted Radiation Treatment Combined with an Immunotherapy Treatment for Dogs with Metastatic Melanoma
In collaboration with the UW Carbone Cancer Center, we are developing a new approach to the treatment of melanoma that has spread beyond the primary tumor (metastatic cancer) utilizing immune responses to recognize and destroy cancer (immunotherapy) in combination with low-dose radiation therapy, which may improve the anti-tumor potency of the immunotherapy.
Dogs will first receive a radioactive imaging agent prior to the performance of 3 daily PET scans. The findings of the PET scans will determine the dose of the radioactive anti-tumor agent which will be delivered intravenously one week later. Two weeks after the radioactive anti-tumor agent is delivered, the dog will receive one conventional radiation therapy treatment, immediately followed by treatment with the intravenous radioactive anti-tumor agent. One week later, an immunotherapy agent will be administered directly into the dog’s tumor, once daily for 3 days. Because the imaging agent and the intravenous radiation agent are radioactive, dogs must remain in the hospital until it is determined that the appropriate level of radioactivity has been reached to allow the dog to return home: this will be approximately 4 – 6 days following administration of the imaging agent or the intravenous radiation treatment.
All costs associated with initial screening to determine eligibility and costs associated with treatment, scans, hospitalizations, and study follow-up are paid for by the study. In addition, a $500 credit will be applied to your UW Veterinary Care account which can be used following your dog’s completion of this protocol.
Osteosarcoma: Evaluation of a Recombinant, Attenuated Listeria Monocytogenes Expressing a Chimeric Human Her2/neu Protein (ADXS31-164c ) in Dogs With Osteosarcoma in the Adjuvant Setting
Bone cancer or osteosarcoma (OSA) is a common, highly aggressive cancer that frequently affects the long bones of large breed dogs. Current therapy consists of limb amputation plus chemotherapy. However, despite therapy, most patients die as a result of the cancer spreading to other parts of their body. The immune system plays an important role in identifying and targeting cancer cells in the body. In this study, we aim to use a new approach to stimulate the body’s own immune system to attack remaining tumor cells in dogs that have undergone limb amputation and chemotherapy for the treatment of OSA. We will use a vaccine made from the bacteria Listeria monocytogenes, which has been genetically modified to express a tumor protein (HER-2/neu) that is found in many cancer cells, including canine bone cancer cells and cancer stem cells. When injected into the bloodstream, the modified Listeria stimulates the immune system to attack cells expressing the HER-2/neu tumor protein. This approach aims to delay and/or prevent the spread of cancer (metastases) following removal of the primary bone cancer tumor (limb amputation) and chemotherapy.
To qualify for this study, we ask that you permit surgical amputation of your dog’s affected limb. Your dog will return to UW Veterinary Care every 3 weeks for 15 weeks for evaluation. On weeks 3, 6, 9 and 12 your dog will receive a dose of carboplatin (standard of care for OSA). Blood work will be done on your dog prior to carboplatin administration. After 15 weeks, your dog will be administered 3 doses of ADXS31-164c. Doses will be administered every 3 weeks for a total of 3 treatments.
Clients of dogs entered into this study will receive financial compensation, which will cover the cost of the initial physical examination and ultrasound, all physical examinations and radiographs, and the costs associated with ADXS31-164c treatment and follow-up evaluations. Clients are responsible for the cost of diagnosis, amputation, and for the carboplatin chemotherapy.
Osteosarcoma with Lung Metastasis: Evaluation of a Novel Anticancer Drug in Combination with a Common Chemotherapy drug for the Treatment of Osteosarcoma Metastasis
Bone cancer (osteosarcoma) is a common, highly aggressive cancer that frequently affects the long bones of large breed dogs. Current therapy consists of limb amputation plus chemotherapy. However, despite therapy, most patients die as a result of the cancer spreading to other parts of their body, most commonly to the lungs. The purpose of this clinical trial is to evaluate the safety and efficacy of a novel anticancer drug (PAC-1) combined with a commonly used chemotherapy drug (doxorubicin) for dogs with osteosarcoma that has spread to their lungs. PAC-1 is a new drug that can sensitize osteosarcoma tumor cells to the killing effect of doxorubicin.
For dogs to be eligible for this clinical trial they must have a confirmed diagnosis of osteosarcoma with spread to the lungs and have had a previous amputation, limb spare or stereotactic radiation of the affected limb. Dogs will receive a total of 4 doses of intravenous doxorubicin (at 2-week intervals) and PAC-1 given orally once daily for 7 days prior to each doxorubicin treatment.
Owners are responsible for eligibility requirements (blood work, chest x-ray, abdominal ultrasound). Following enrollment, the study will cover the costs of PAC-1 and doxorubicin, and all study-related evaluations and follow-up.
2) STUDIES FOR ANY CANCER TYPE
Cats with Any Cancer: Safety Evaluation of Palladia (Toceranib Phosphate) in Combination with Doxorubicin
Previous studies have shown that the drug Palladia (toceranib) can reverse resistance to doxorubicin (a commonly used anticancer drug). We have recently completed a study evaluating toceranib in combination with doxorubicin as treatment for cancer in dogs. The combination was well tolerated and the maximum tolerated dose of doxorubicin when combined with Palladia was determined. The goal of this study is to evaluate the safety and maximum tolerated dose of combination toceranib and doxorubicin in cats with naturally occurring cancer.
Cats that have a confirmed diagnosis of new or recurrent cancer may be eligible for this study. Cats will receive Palladia every other day (given orally by the owner). Doxorubicin will be administered intravenously every 3 weeks for a total of 4 treatments. Cats will be evaluated prior to each doxorubicin treatment and one week after each treatment for assessment of side effects and efficacy of this combined treatment.
The owner is responsible for the cost of initial staging (including pretreatment labwork and pretreatment blood pressure measurement) and recheck examination fees throughout the study period. The study will cover all other study-related costs.
Dogs With Any Cancer (except mast cell tumor or hemangiosarcoma): Evaluation of a Novel Oral Anticancer Agent
This clinical trial led by the National Cancer Institute is evaluating the safety and effectiveness of CB-5339, a novel anticancer agent, when given orally to dogs with cancer. Dogs with any cancer (except mast cell tumors or hemangiosarcoma) may be eligible for this study. CB-5339 is administered for orally, once daily for 4 consecutive days the first week and again for 4 days the second week.
Tumor biopsies will be performed prior to treatment and again on study days 1, 2, 8, and 22. Blood samples will be collected prior to treatment and again on study days 1, 2, 8, 15, and 22. Costs related to the study will be covered by the study. In addition, a $1,000 credit will be applied to your UW Veterinary Care account which can be used towards additional treatment of your dog’s cancer following your dog’s completion of this protocol.
Healthy Dogs of Certain Breeds: Vaccination Against Canine Cancer Study
UW Veterinary Care’s Oncology Service is recruiting dogs for the Vaccination Against Canine Cancer Study (VACCS trial), the largest clinical trial conducted to date for canine cancer. The goal of the VACCS trial is to evaluate a new vaccine strategy for the prevention, rather than treatment of dogs with cancer.
Healthy dogs of certain breeds, 6 to 10 years of age, will be randomized to receive either a series of vaccines similar to other routine vaccines that are given to dogs currently, or placebo vaccines. Dogs will live at home and be checked 2-3 times yearly for 5 years after enrollment. A financial incentive will be offered to defray the cost associated with diagnostics and treatment of any cancers that dogs develop, regardless of whether they are receiving vaccine or placebo.
In addition to potentially providing a new strategy for cancer prevention in dogs, if successful, this study could provide important justification for eventually looking at a similar approach in humans.
4) BIOPSY STUDIES
Dogs with Mast Cell Tumors
The General Surgery Service is looking for dogs with mast cell tumors. The goal of this study is to compare the histopathological grade of samples obtained from a punch biopsy to samples obtained from a whole tumor specimen. The surgeons surgically remove the tumor in a routine manner according to the normal standard of care. Punch biopsies are taken of the removed tumor. Three pathologists examine the punch biopsies, along with the complete tumor samples, to determine the grade of mast cell tumor. The results are then compared. The goal is to determine if mast cell tumors can be accurately graded from a smaller, less invasive, sample size. For more information, contact Dr Robb Hardie at email@example.com.